These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 16294039)

  • 21. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
    Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
    Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
    Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
    PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival.
    Dayyani F; Wang J; Yeh JR; Ahn EY; Tobey E; Zhang DE; Bernstein ID; Peterson RT; Sweetser DA
    Blood; 2008 Apr; 111(8):4338-47. PubMed ID: 18258796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
    Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
    Br J Haematol; 2006 Sep; 134(6):616-9. PubMed ID: 16938118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
    Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
    J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.
    Hatlen MA; Wang L; Nimer SD
    Front Med; 2012 Sep; 6(3):248-62. PubMed ID: 22875638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
    Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
    Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
    [No Abstract]   [Full Text] [Related]  

  • 28. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
    Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
    Chen Z; Shao YL; Wang LL; Lin J; Zhang JB; Ding Y; Gao BB; Liu DH; Gao XN
    Oncogene; 2021 Jun; 40(22):3786-3798. PubMed ID: 33958724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of genomic AML1-ETO fusions in childhood leukemia.
    Xiao Z; Greaves MF; Buffler P; Smith MT; Segal MR; Dicks BM; Wiencke JK; Wiemels JL
    Leukemia; 2001 Dec; 15(12):1906-13. PubMed ID: 11753612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
    DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
    Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
    Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells.
    Trombly DJ; Whitfield TW; Padmanabhan S; Gordon JA; Lian JB; van Wijnen AJ; Zaidi SK; Stein JL; Stein GS
    BMC Genomics; 2015 Apr; 16(1):309. PubMed ID: 25928846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
    Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
    Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Liu J; Lu W; Liu S; Wang Y; Li S; Xu Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Leuk Res; 2018 May; 68():15-21. PubMed ID: 29518627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature.
    Fortier JM; Payton JE; Cahan P; Ley TJ; Walter MJ; Graubert TA
    Leukemia; 2010 May; 24(5):950-7. PubMed ID: 20376082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Duployez N; Marceau-Renaut A; Boissel N; Petit A; Bucci M; Geffroy S; Lapillonne H; Renneville A; Ragu C; Figeac M; Celli-Lebras K; Lacombe C; Micol JB; Abdel-Wahab O; Cornillet P; Ifrah N; Dombret H; Leverger G; Jourdan E; Preudhomme C
    Blood; 2016 May; 127(20):2451-9. PubMed ID: 26980726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.
    Yuan Y; Zhou L; Miyamoto T; Iwasaki H; Harakawa N; Hetherington CJ; Burel SA; Lagasse E; Weissman IL; Akashi K; Zhang DE
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10398-403. PubMed ID: 11526243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AML1-ETO positive AML: first report from India.
    Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
    Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.